Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
August 16, 2021 10:00 AM EDTUpdated 11:24 AM
Deals

In­side the deal: Sanofi flipped from sell-off to merg­er in lead up to $3.2B Trans­late buy­out

Kyle Blankenship

Pri­or to its $3.2 bil­lion ac­qui­si­tion of mR­NA play­er Trans­late Bio ear­li­er this month, French drug­mak­er Sanofi con­sid­ered dump­ing a quar­ter of its shares …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times